PSA screening
Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening
8
Cost implications of PSA screening differ by age
8
Comment on the Canadian Task Force on the Preventive Health Care on PSA Screening
5
Exploring patient perceptions of PSA screening for prostate cancer
6
PSA Screening for Prostate Cancer in Men under the Age of 65: A Review of Current Practice
26
A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening—a qualitative analysis
8
The relationship between Agent Orange and prostate specific antigen: a comparison of a hotspot and a non-sprayed area in Vietnam
5
Understanding the PSA test
19
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
8
Use of prostate-specific antigen testing in Medicare beneficiaries
10
Simulation Optimization of Prostate Cancer Screening Using a Parallel Genetic Algorithm.
68
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
8
Risk-Based Simulation Optimization of PSA-Based Prostate Cancer Screening
250
Who and when should we screen for prostate cancer? Interviews with key opinion leaders
17
Burden of PSA testing
46
Role of Prostate Volume in the Early Detection of Prostate Cancer in a Cohort with Slowly Increasing Prostate Specific Antigen
5
Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
6
Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
6
Sentencing Principles in the High Court and the PSA
18
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
18